Credit Suisse Downgrades Durata Therapeutics (DRTX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Roth Capital Downgrades Durata Therapeutics (DRTX) to Neutral
October 15, 2014 6:54 AM EDTRoth Capital downgraded Durata Therapeutics (NASDAQ: DRTX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Durata Therapeutics click here. For more ratings news on Durata Therapeutics click here.
Shares of Durata Therapeutics closed at $23.74 yesterday.
... More